Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Timothy P. Hughes,1,2 Andreas Hochhaus,3 Hagop M. Kantarjian,4 Francisco Cervantes,5 François Guilhot,6 Dietger Niederwieser,7 Philipp D. le Coutre,8 Gianantonio Rosti,9 Gert Ossenkoppele,10 Clarisse Lobo,11 Hirohiko Shibayama,12 Xiaolin Fan,13 Hans D. Menssen,14 Charisse Kemp,15 Richard A. Larson,15 and Giuseppe Saglio16

1South Australian Health and Medical Research Institute, University of Adelaide, Australia; 2Division of Haematology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia; 3Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Germany; 4The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5IDIBAPS, University of Barcelona, Spain; 6Inserm CIC 0802, CHU de Poitiers, France; 7Division of Hematology and Oncology, University of Leipzig, Germany; 8Charité - Universitätsmedizin Berlin, Germany; 9University of Bologna, Italy; 10VU University Medical Center, Amsterdam, The Netherlands; 11HEMORIO, Rio de Janeiro, Brazil; 12Osaka University Graduate School of Medicine, Osaka, Japan; 13Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; 14Novartis Pharma AG, Basel, Switzerland; 15The University of Chicago, IL, USA; and 16University of Turin, Orbassano, Italy

© 2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.091272
Manuscript received on June 4, 2013. Manuscript accepted on February 5, 2014.
Correspondence: timothy.hughes@health.sa.gov.au
Supplementary Appendix.

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily

Authors: Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Francisco Cervantes, François Guilhot, Dietger Niederwieser, Philipp D. le Coutre, Gianantonio Rosti, Gert Ossenkoppele, Clarisse Lobo, Hirohiko Shibayama, Xiaolin Fan, Hans D. Menssen, Charisse Kemp, Richard A. Larson, Giuseppe Saglio

Detailed methods

Evaluating Nilotinib Efficacy and Safety in Clinical Trials—Newly Diagnosed Patients (ENESTnd) Core Study: Patients, Study Design, and Treatments

The study design of the phase 3, randomized, open-label ENESTnd trial has been previously reported. Briefly, newly diagnosed patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) were randomized 1:1:1 to receive nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily. Randomization was stratified according to Sokal risk score at the time of diagnosis. Patients enrolled in the imatinib arm of ENESTnd who had suboptimal response or treatment failure were allowed to undergo dose escalation of imatinib from 400 mg once daily to 400 mg twice daily, if tolerable. Dose escalation of nilotinib was not permitted in the core study.

ENESTnd Core Study: Analysis of Suboptimal Response and Treatment Failure

Definitions of suboptimal response and treatment failure in ENESTnd were based on those recommended by the European LeukemiaNet, with some modifications. Suboptimal response was defined as follows:
less than a complete hematologic response (CHR) at 3 months, less than a partial cytogenetic response (PCyR; 35% Ph+ cells) at 6 months, less than a complete cytogenetic response (CCyR; 0% Ph+ cells) at 12 months, less than a major molecular response (MMR; BCR-ABL on the international scale [BCR-ABLIS] ≤ 0.1%) at 18 months or later, or loss of MMR at any time. Loss of MMR required confirmation by a second assessment unless it was associated with loss of CHR, loss of CCyR, progression to accelerated phase/blast crisis (AP/BC), or CML-related death.

Treatment failure was defined as follows: less than CHR or no cytogenetic response (CyR; 95% Ph+ cells) at 6 months, less than PCyR at 12 months, less than CCyR at 18 months, or loss of CHR, loss of PCyR, loss of CCyR, or progression to AP/BC at any time. Loss of CHR required confirmation unless it was associated with progression to AP/BC or CML-related death; loss of PCyR or CCyR was confirmed by a second cytogenetic analysis ≥ 4 weeks later unless it was associated with loss of CHR, progression to AP/BC, or CML-related death.

Incidences of suboptimal response and treatment failure were reported cumulatively by 6, 12, and 18 months. For each patient, only their worst response at or before each time point was counted (eg, a patient who satisfied the criteria for treatment failure at 6 months and suboptimal response at 12 months was considered to have treatment failure by 12 months).

References